Phaseline

Companies › Nanjing Sanhome Pharmaceutical

Nanjing Sanhome Pharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SH-1028 tablets
EGFR tyrosine kinase inhibitor
EGFRPhase 3Non-small Cell Lung CancerFeb 2028
SH006–Phase 1Liver CancerDec 2026
SH009–Phase 1Liver Cancer (Locally Advanced or Metastatic)Dec 2026
SH3765
unclear mechanism
–Phase 1HR+ / HER2- Advanced Breast CancerJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07390838SH009Phase 1Liver Cancer (Locally Advanced or Metastatic)OncologyDec 2026
NCT07362264SH006Phase 1Liver CancerOncologyDec 2026
NCT07557004SH3765Phase 1HR+ / HER2- Advanced Breast CancerOncologyJun 2027
NCT06080776SH-1028 tabletsPhase 3Non-small Cell Lung CancerOncologyFeb 2028

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Jiangsu Alphamab Biopharmaceuticals Jiangsu Aosaikang Pharmaceutical ArriVent BioPharma HC Biopharma Wayshine Biopharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.